Neurology · Multiple SclerosisRegulatory Approvalcommercialmid-term

FDA Submission Update for Dalfampridine by Accord Healthcare

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:33:23 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of an ANDA for Dalfampridine by Accord Healthcare signals the potential entry of a generic competitor into the market. This could lead to significant pricing pressures and market share erosion for current brand holders, necessitating strategic responses. Regulatory context from FDA (FDA AP — DALFAMPRIDINE (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the competitive landscape for Dalfampridine and consider strategies to mitigate potential market share loss. The strongest clinical anchor is Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects (ClinicalTrials.gov), mechanism alignment (io ). In Neurology · Multiple Sclerosis, 7 regulatory and 3 competitive items passed relevance filtering for Dalfampridine.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This submission indicates potential market entry for a generic version of Dalfampridine, which may impact pricing and market share of existing brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DALFAMPRIDINE (SUPPL) (FDA). Entity match (dalfampridine); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review process by the FDA indicates a timeline for potential approval, which could affect the competitive landscape depending on the outcome.

Key Risks

Elevated medium regulatory exposure for Dalfampridine could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)) could weigh on Dalfampridine through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The introduction of a generic version of Dalfampridine could substantially reduce prices and impact revenue streams for existing brands, altering competitive dynamics in the neurology market.
Upside for Dalfampridine may improve if Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Dalfampridine may improve if Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Dalfampridine may improve if Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study. (PubMed) delivers favorable follow-through.
Lead sponsor: Genentech, Inc.. The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements for the ANDA.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DALFAMPRIDINE (SUPPL)
FDAhigh relevance
Entity match (dalfampridine); Regulatory pathway relevance (nda)
FDA document
View source
Regulation of AI in Healthcare
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
MHRA landmark report reveals public views on AI in healthcare
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Data Standards Program Strategic Plan and Board
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Real-World Evidence Submissions to the Center for Drug Evaluation and Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Real-World Exploratory Study on the Sleep-Improving Efficacy of Dong'e Brand Ejiao Yuanjiang
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir
Humanexa Signalsmedium relevance
Moderate corpus alignment

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Dalfampridine
existing brand manufacturers

Commercial impact

high

The introduction of a generic version of Dalfampridine could substantially reduce prices and impact revenue streams for existing brands, altering competitive dynamics in the neurology market.

Regulatory impact

medium

The standard review process by the FDA indicates a timeline for potential approval, which could affect the competitive landscape depending on the outcome.

What to watch

Monitor the FDA's review timeline and any subsequent approval announcements for the ANDA.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.